Sapient Discovery's expert team of computational chemists and structural biologists have a track record of successfully identifying lead molecules, so far for more than eighteen different protein drug targets, comprising a diverse set of structural classes including protein kinases, protein phosphatases, proteases, GPCRs, and receptors for cytokines or other regulatory molecules. Some of these are in pre-clinical development, others are in clinical trials, and in 2006 the first received government approval in Europe for treatment of an important cardiovascular disease (pulmonary arterial hypertension).

Sapient Discovery applies its extensive structural design expertise, large-scale proprietary structural databases, and leading-edge proprietary computational methodologies in partnership with the scientists of our client companies to accelerate the drug discovery and drug optimization processes.

Copyright © 2006 - 2024 Sapient Discovery LLC. All rights reserved.